Targeting dendritic cells with antigen-containing liposomes: antitumour immunity
暂无分享,去创建一个
J. Altin | C. Parish | Christopher R Parish | Joseph G Altin | Christina L van Broekhoven | C. L. van Broekhoven | Christina L. van Broekhoven
[1] T. Elliott,et al. The processing of antigens delivered as DNA vaccines , 2004, Immunological reviews.
[2] C. Figdor,et al. DC-SIGN and LFA-1: a battle for ligand. , 2001, Trends in immunology.
[3] H. Wagner. The immunobiology of the TLR9 subfamily. , 2004, Trends in immunology.
[4] Michel C. Nussenzweig,et al. Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.
[5] Carl G. Figdor,et al. DC-SIGN–ICAM-2 interaction mediates dendritic cell trafficking , 2000, Nature Immunology.
[6] R. Steinman,et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. , 2000, Blood.
[7] C. Figdor,et al. Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.
[8] W. Pardridge,et al. Receptor-Mediated Gene Targeting to Tissues In Vivo Following Intravenous Administration of Pegylated Immunoliposomes , 2001, Pharmaceutical Research.
[9] B. Frisch,et al. Synthesis of an amphiphilic tetraantennary mannosyl conjugate and incorporation into liposome carriers. , 2003, Bioorganic & medicinal chemistry letters.
[10] B. Coombes,et al. Dendritic cell discoveries provide new insight into the cellular immunobiology of DNA vaccines. , 2001, Immunology letters.
[11] Y. Barenholz,et al. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. , 2000, Journal of immunotherapy.
[12] A. Gabizon,et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[13] R. Steinman,et al. Immune Tolerance After Delivery of Dying Cells to Dendritic Cells In Situ , 2002, The Journal of experimental medicine.
[14] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[15] P. Coulie,et al. Tumor antigens recognized by T cells. , 1997, Immunology today.
[16] E. Padovan,et al. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes , 2004, British Journal of Cancer.
[17] R. Issels,et al. The role of heat shock protein (hsp70) in dendritic cell maturation: Hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors , 2001, European journal of immunology.
[18] S. Chen,et al. Targeting dendritic cells to enhance DNA vaccine potency. , 2001, Cancer research.
[19] A. Hill,et al. Role of transfection in the priming of cytotoxic T-cells by DNA-mediated immunization. , 2002, Vaccine.
[20] E. Moase,et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.
[21] J. Norton,et al. Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12. , 2004, The Journal of surgical research.
[22] H. Nisenbaum,et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] T M Allen,et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.
[24] K. Black,et al. HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells , 2004, Cancer Research.
[25] J. Thompson,et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Papahadjopoulos,et al. Liposomes revisited , 1995, Science.
[27] D. Crommelin,et al. Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. , 2001, Biochimica et biophysica acta.
[28] C. Alving,et al. Liposomes as carriers of antigens and adjuvants. , 1991, Journal of immunological methods.
[29] Mark J. Miller,et al. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[30] A. Gabizon,et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. , 1991, Biochimica et biophysica acta.
[31] I. Frazer,et al. Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. , 2002, Cancer research.
[32] G. Gregoriadis. The immunological adjuvant and vaccine carrier properties of liposomes. , 1994, Journal of drug targeting.
[33] A. Eggermont,et al. Pegylated liposomal tumor necrosis factor‐α results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma‐bearing rats , 2002, International journal of cancer.
[34] F. Marincola,et al. Natural T cell immunity against cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] D. Weiner,et al. DNA vaccination: antigen presentation and the induction of immunity , 2000, Journal of leukocyte biology.
[36] Jianping Pan,et al. Interferon-γ is an autocrine mediator for dendritic cell maturation , 2004 .
[37] H. Ueno,et al. Dendritic cells as vectors for immunotherapy of cancer. , 2003, Seminars in cancer biology.
[38] A. Morita,et al. Dendritic cells in genetic immunization , 1999, Journal of leukocyte biology.
[39] M. Tsan,et al. Endogenous ligands of Toll‐like receptors , 2004, Journal of leukocyte biology.
[40] C. Sousa,et al. Phagocytosis of antigens by Langerhans cells in vitro , 1993, The Journal of experimental medicine.
[41] S. Rutella,et al. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. , 2004, Immunology letters.
[42] E. Gilboa,et al. Immunotherapy of cancer with dendritic-cell-based vaccines , 1998, Cancer Immunology, Immunotherapy.
[43] Amarnath Sharma,et al. Liposomes in drug delivery: Progress and limitations , 1997 .
[44] C J Turtle,et al. Dendritic cells in tumor immunology and immunotherapy. , 2004, Current drug targets.
[45] N. Kadowaki,et al. Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial Antigens , 2001, The Journal of experimental medicine.
[46] S. Sad,et al. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. , 2003, Cancer research.
[47] B. '. ’t Hart,et al. Yin-Yang regulation of autoimmunity by DCs. , 2004, Trends in immunology.
[48] G. Chikh,et al. Liposomal Delivery of CTL Epitopes to Dendritic Cells , 2002, Bioscience reports.
[49] H. Thérien,et al. Effect of liposomal antigens on the priming and activation of the immune system by dendritic cells. , 2002, International immunopharmacology.
[50] A. Cavazza,et al. Degradation of the tumor antigen epitope gp100(280-288) by fibroblast-associated enzymes abolishes specific immunorecognition. , 2004, Biochimica et biophysica acta.
[51] P. Foster,et al. Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells , 2003, The Journal of experimental medicine.
[52] Praveen Elamanchili,et al. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. , 2004, Vaccine.
[53] F. Foss,et al. Immunologic mechanisms of antitumor activity. , 2002, Seminars in oncology.
[54] B. Stockinger,et al. DNA Vaccination: Transfection and Activation of Dendritic Cells as Key Events for Immunity , 1999, The Journal of experimental medicine.
[55] R. Steinman,et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing , 1995, Nature.
[56] S. Simões,et al. Gene delivery mediated by cationic liposomes: from biophysical aspects to enhancement of transfection. , 1999, Molecular membrane biology.
[57] Philippe Bousso,et al. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes , 2003, Nature Immunology.
[58] R. Steinman,et al. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.
[59] D. Scott‐Algara,et al. Idiotype‐pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia , 2003, British journal of haematology.
[60] J. Altin,et al. Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-ligand interactions on model membranes. , 2001, Biochimica et biophysica acta.
[61] D. Pardoll,et al. Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance , 2004, Nature Immunology.
[62] Sven Frokjaer,et al. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. , 2004, Vaccine.
[63] T. Luft,et al. ISCOM based vaccines for cancer immunotherapy. , 2004, Vaccine.
[64] T. Whiteside,et al. Dendritic cell biology and cancer therapy , 2004, Cancer Immunology, Immunotherapy.
[65] M. Salgaller,et al. Current Methods for Loading Dendritic Cells With Tumor Antigen for the Induction of Antitumor Immunity , 2002, Journal of immunotherapy.
[66] C. Demangel,et al. Targeting Dendritic Cells with Antigen-Containing Liposomes , 2004, Cancer Research.
[67] M. Diamond,et al. The leukocyte integrin p150,95 (CD11c/CD18) as a receptor for iC3b. Activation by a heterologous beta subunit and localization of a ligand recognition site to the I domain. , 1994, Journal of immunology.
[68] F Ambrosch,et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. , 1997, Vaccine.
[69] P. Allen,et al. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy. , 2003, International immunology.
[70] A. Gabizon,et al. The role of surface charge and hydrophilic groups on liposome clearance in vivo. , 1992, Biochimica et biophysica acta.
[71] J. Altin,et al. A novel system for convenient detection of low‐affinity receptor–ligand interactions: Chelator‐lipid liposomes engrafted with recombinant CD4 bind to cells expressing MHC class II , 2001, Immunology and cell biology.
[72] Nina Bhardwaj,et al. Danger signals: a time and space continuum. , 2004, Trends in molecular medicine.
[73] L. Huang,et al. Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I-restricted antigen presentation pathway. , 1994, ImmunoMethods.
[74] G. Belz,et al. Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.
[75] L. Richer,et al. The development of IL-2 conjugated liposomes for therapeutic purposes. , 1998, Biochimica et biophysica acta.
[76] C. Alving,et al. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. , 1992, Biochimica et biophysica acta.
[77] Siamon Gordon,et al. Pattern Recognition Receptors Doubling Up for the Innate Immune Response , 2002, Cell.
[78] P. Wils,et al. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors , 2002, Gene Therapy.
[79] S. Zelenay,et al. Immunostimulatory effects of plasmid DNA and synthetic oligodeoxynucleotides , 2003, European journal of immunology.
[80] R. Steinman,et al. The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal Compartments , 2000, The Journal of cell biology.
[81] Hongmei Shen,et al. Gene delivery to dendritic cells facilitated by a tumor necrosis factor alpha-competing peptide. , 2004, Molecular immunology.
[82] C. Harding,et al. Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. , 1992, Journal of immunology.
[83] R. Banerjee,et al. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[84] C. Leclerc,et al. New tools for antigen delivery to the MHC class I pathway. , 2004, Trends in immunology.
[85] Michel C. Nussenzweig,et al. Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.
[86] M. Manjili,et al. Cancer immunotherapy and heat-shock proteins: promises and challenges , 2004, Expert opinion on biological therapy.
[87] L. Appleman,et al. T cell anergy and costimulation , 2003, Immunological reviews.
[88] Y. Barenholz,et al. Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. , 1997, Journal of immunotherapy.
[89] J. Altin,et al. A novel approach for modifying tumor cell‐derived plasma membrane vesicles to contain encapsulated IL‐2 and engrafted costimulatory molecules for use in tumor immunotherapy , 2002, International journal of cancer.
[90] A. El-Aneed,et al. An overview of current delivery systems in cancer gene therapy. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[91] R. K. Bright,et al. TUMOR-ASSOCIATED ANTIGENS: FROM DISCOVERY TO IMMUNITY , 2003, International reviews of immunology.
[92] V. Cerundolo,et al. Dendritic cells: a journey from laboratory to clinic , 2004, Nature Immunology.
[93] D. Papahadjopoulos,et al. Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. , 1992, Biochimica et biophysica acta.
[94] H. Levitsky,et al. Specific Immunotherapy by Genetically Engineered APCs: The “Guided Missile” Strategy1 , 2001, The Journal of Immunology.
[95] Polly Matzinger,et al. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.
[96] R. Steinman,et al. Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein , 2003 .
[97] Giovanni Melioli,et al. Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells , 2002, The Journal of experimental medicine.
[98] S. Kennel,et al. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[99] J. Wilschut,et al. Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs , 2002, Bioscience reports.
[100] B. Bodey,et al. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy. , 2004, In vivo.
[101] A. Ulrich. Biophysical Aspects of Using Liposomes as Delivery Vehicles , 2002, Bioscience reports.
[102] E. Padovan,et al. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. , 2004, Vaccine.
[103] Y. Aramaki,et al. Interferon-γ inductive effect of liposomes as an immunoadjuvant , 1995 .
[104] A. Cavazza,et al. Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. , 2004, Clinical immunology.
[105] M. Wauben,et al. Anergic T cells as active regulators of the immune response. , 2000, Human immunology.
[106] P. Tyler,et al. Liposomal delivery of antigen to human dendritic cells. , 2003, Vaccine.
[107] Antonio Lanzavecchia,et al. The Dendritic Cell-Specific Adhesion Receptor DC-SIGN Internalizes Antigen for Presentation to T Cells1 , 2002, The Journal of Immunology.
[108] C. Reis e Sousa,et al. Dendritic cells: immunobiology and cancer immunotherapy. , 2004, Immunity.
[109] R. Schreiber,et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. , 2000, Immunity.
[110] F. Falkenberg,et al. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. , 1999, Journal of immunotherapy.